Immunocore Holdings plc (NASDAQ:IMCR) Shares Sold by Aquatic Capital Management LLC

Aquatic Capital Management LLC decreased its position in Immunocore Holdings plc (NASDAQ:IMCR - Free Report) by 87.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,400 shares of the company's stock after selling 9,500 shares during the period. Aquatic Capital Management LLC's holdings in Immunocore were worth $41,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in IMCR. Groupama Asset Managment bought a new position in shares of Immunocore in the fourth quarter valued at approximately $17,700,000. T. Rowe Price Investment Management Inc. grew its position in shares of Immunocore by 3.1% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 6,700,208 shares of the company's stock worth $197,657,000 after buying an additional 200,373 shares during the last quarter. Primecap Management Co. CA lifted its holdings in Immunocore by 8.0% in the fourth quarter. Primecap Management Co. CA now owns 2,668,550 shares of the company's stock worth $78,722,000 after buying an additional 196,530 shares during the period. Principal Financial Group Inc. lifted its stake in shares of Immunocore by 25.0% in the 3rd quarter. Principal Financial Group Inc. now owns 546,318 shares of the company's stock valued at $17,007,000 after purchasing an additional 109,206 shares during the period. Finally, BIT Capital GmbH grew its holdings in Immunocore by 182.7% in the fourth quarter. BIT Capital GmbH now owns 67,840 shares of the company's stock worth $2,001,000 after purchasing an additional 43,840 shares during the period. 84.50% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Immunocore

In other Immunocore news, Director Bros. Advisors Lp Baker purchased 807,338 shares of Immunocore stock in a transaction on Monday, March 17th. The shares were purchased at an average cost of $29.72 per share, with a total value of $23,994,085.36. Following the completion of the transaction, the director now directly owns 2,144,060 shares in the company, valued at approximately $63,721,463.20. This represents a 60.40% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 10.40% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on IMCR shares. Mizuho decreased their price objective on shares of Immunocore from $38.00 to $33.00 and set a "neutral" rating for the company in a report on Monday, April 7th. JPMorgan Chase & Co. dropped their target price on shares of Immunocore from $54.00 to $50.00 and set an "overweight" rating for the company in a research report on Monday, April 14th. Morgan Stanley reaffirmed an "equal weight" rating and issued a $35.00 price target on shares of Immunocore in a report on Friday, March 7th. HC Wainwright reaffirmed a "buy" rating and set a $100.00 target price on shares of Immunocore in a research note on Wednesday, March 12th. Finally, Oppenheimer raised their target price on shares of Immunocore from $85.00 to $86.00 and gave the stock an "outperform" rating in a research report on Thursday. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and six have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Immunocore currently has a consensus rating of "Moderate Buy" and an average target price of $58.13.

Immunocore Stock Up 0.6%

NASDAQ IMCR traded up $0.17 during trading on Monday, reaching $28.57. 34,393 shares of the company's stock were exchanged, compared to its average volume of 428,997. The company has a debt-to-equity ratio of 1.03, a quick ratio of 3.76 and a current ratio of 3.78. Immunocore Holdings plc has a 1 year low of $23.15 and a 1 year high of $59.82. The company has a 50 day moving average price of $28.81 and a two-hundred day moving average price of $30.14. The stock has a market cap of $1.43 billion, a P/E ratio of -30.19 and a beta of 0.75.

Immunocore (NASDAQ:IMCR - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.45. The company had revenue of $125.13 million for the quarter, compared to analysts' expectations of $108.82 million. Immunocore had a negative net margin of 15.87% and a negative return on equity of 12.84%. Immunocore's revenue was up 33.6% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.49) EPS. On average, equities research analysts anticipate that Immunocore Holdings plc will post -0.94 EPS for the current fiscal year.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.